WillItSurvive
Medical technology and health companies · subsidiary of Fresenius SE & Co. KGaA · Germany

Fresenius Medical Care

freseniusmedicalcare.com ↗

World's largest dialysis provider, running clinics and making the machines patients depend on.

Hard to displace
Assessed 22 July 2026 · Evidence as of 22 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 22 July 2026 · Checkable from 2026-2027 · Every call on the record Checkpoint: Rulings or settlement in the DaVita price-fixing class action and FTC non-compete probe
The call

Two companies run most of America's dialysis chairs, and no software or algorithm changes who owns the machines and the licenses.

Fresenius Medical Care operates dialysis clinics and makes dialysis machines, treating patients with kidney failure three times per week. It is hard to replace because dialysis requires licensed staff, expensive equipment, and long-term contracts with insurance companies and hospitals, plus the company owns its own equipment maker. DaVita is its only real competitor (they split the market 77%), and AI cannot do the physical work of connecting needles or running machines. The thing that could change everything is if antitrust lawsuits force the company to lower prices to commercial insurance plans, which would hurt profits but probably not put the company out of business.

Why
01
AI pressure: None apparent. AI can help schedule staff or flag risk scores, but it cannot put a needle in a patient's arm three times a week. Could AI do the core job? Unlikely.
02
Bigger players: DaVita Inc.. DaVita and Fresenius split roughly 77% of the U.S. market between them and have coexisted for decades rather than fight for share. Could a giant copy it? No, they are blocked.
03
What protects it. Licensed clinics, government payer contracts, and owning NxStage's machine supply make this business nearly impossible to replicate quickly.
What would change this call
2026-27 ruling or settlement in the Sept 2025 price-fixing class action against Fresenius and DaVita. Would show whether the duopoly's market allocation practices face legal limits on pricing power.
FTC decision on physician non-compete clause probe reported in 2024. Would show whether regulators restrict a tool FME uses to lock in referring physicians.
Execution outcome of the 5008X CAREsystem US rollout planned for 2026. Would show whether FME's equipment platform strengthens its integration moat versus DaVita.
Key numbers
  • 3,601 clinics treating 292,000 patients (2025-12-31)
  • Operating margin 11.3%, up from 7.9% in 2022 (2025-12-31)
  • Revenue €22,554M, up 8% organic (2025-12-31)
Named risks
  • Colorado antitrust class action alleging price-fixing and market allocation with DaVita filed September 2025. Severity: high
  • 2024 FTC probe into physician non-compete clauses could restrict payer contracting practices. Severity: medium
  • 2024 Class I FDA recall of 2008 Series hemodialysis machines with ongoing lawsuit exposure through July 2026. Severity: medium
  • 2026 guidance of broadly flat revenue signals limited near-term growth and sensitivity to FX and divestitures. Severity: low
  • Legacy litigation including GranuFlo and False Claims Act qui tam cases active through 2025-2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
DaVita Inc.contestingStable US duopoly holding 77.1% of facilities combined as of 2019, coexisting rather than displacing
Strive Healthgaining onValue-based nephrology upstart competing for FME's smaller Value-Based Care segment as of 2025-2026
Interwell Healthgaining onAcquired Cricket Health to expand risk-based nephrology contracts, pressuring FME's payer segment
U.S. Renal CarecontestingRegional US chain with 500-plus facilities competing at local market level per 2025-11-14 analysis
Questions people ask
Is Fresenius Medical Care profitable in 2026?
Yes. FME's operating margin hit 11.3% in FY2025, up from 7.9% in 2022, with operating income excluding special items growing 27% in 2025. Guidance for 2026 is broadly flat revenue but margin held within its mid-term target band, per its February 24, 2026 earnings release.
Could AI replace Fresenius Medical Care?
No. Dialysis requires physical machines, needles, and licensed clinical staff in-person; AI only augments decision-support and back-office layers. FME is building AI tools via a January 2026 SAP partnership and its kinexus platform previewed May 27, 2026, but core treatment delivery stays human and physical.
Who is Fresenius Medical Care's biggest competitor?
DaVita Inc. is FME's primary rival; together they held about 77.1% of US dialysis facilities in 2019, up from 59.1% in 2005, forming an entrenched duopoly. As of a November 14, 2025 estimate, FME held about 38% US share versus DaVita's 35%.
Who owns Fresenius Medical Care?
Fresenius Medical Care is publicly traded on Frankfurt (FME) and NYSE (FMS). Parent Fresenius SE remains its largest shareholder at approximately 29% of share capital as of December 31, 2025, following a November 2023 legal deconsolidation from an AG structure.
Is Fresenius Medical Care laying off employees?
Headcount has declined from about 112,000 at end of 2024 to roughly 110,000 by December 31, 2025, driven by divestitures of 391 facilities and about 12,600 employees since 2023 as part of an ongoing portfolio optimization program.
Does Fresenius Medical Care face antitrust risk?
Yes. A September 2025 amended class-action complaint in Colorado federal court alleges FME and DaVita conspired to fix prices and allocate markets, and the FTC reportedly opened a 2024 probe into physician non-compete clauses. Rulings expected in the 2026 to 2027 window could cap commercial pricing power.
Timeline
  • 2026-05-27Previewed kinexus digital home dialysis platform at ERA Congress 2026
  • 2026-02-24Reported FY2025 results: 27% operating income growth, 11.3% margin
  • 2026-01-19Announced strategic AI partnership intent with SAP for digital backbone
  • 2025-09-01Amended antitrust class action filed in Colorado alleging price-fixing with DaVita
  • 2025-08-01Launched EUR 1 billion two-tranche share buyback program
  • 2024-01-01FTC reportedly opened probe into physician non-compete clauses
  • 2024-01-01FDA Class I recall issued for Fresenius 2008 Series hemodialysis machines
  • 2023-11-30Converted from KGaA to AG, deconsolidating from parent Fresenius SE
Revision history
22 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Epic SystemsPro MedicusCochlear Limited
More in Medical technology and health companies →
Sources